CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations - eScholarship

Elad Ziv,Alan H.B. Wu,Michael A. Province,Matthew Philip Goetz,Hiltrud Brauch,Da Flockhart,Jm Hebert,Ryan M. Whaley,Vera Jean Suman,Werner Schroth,Stefan Winter,Hitoshi Zembutsu

CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations - eScholarship

2014

Elad Ziv
Alan H.B. Wu
Michael A. Province
Matthew Philip Goetz
Hiltrud Brauch
Da Flockhart
Jm Hebert
Ryan M. Whaley
Vera Jean Suman
Werner Schroth
Stefan Winter
Hitoshi Zembutsu

The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy regarding cytochrome P450 2D6 (CYP2D6) status and clinical outcomes in tamoxifen therapy. We performed a meta-analysis on data from 4,973 tamoxifen-treated p

Keywords:

Pharmacogenomics
Tamoxifen
Meta-analysis
Oncology
Adjuvant
Pharmacology
Genotype
Internal medicine
CYP2D6
Tamoxifen therapy
Medicine
adjuvant tamoxifen

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations